Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
View original at globenewswire.comRevolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
RM-055 preferentially suppressed RAS pathway activation in KRAS G12 mutant tumors over normal tissues, suggesting potential for enhanced therapeutic window
60% confidenceRM-055 significantly reduced RAS-GTP levels in cells, leading to inhibition of downstream RAS signaling and tumor cell proliferation
60% confidenceAdditional strategies are needed to counter emergent resistance to RAS inhibitors and further extend clinical benefit for patients with RAS mutant cancers
60% confidenceAt well-tolerated doses, RM-055 demonstrated robust and durable antitumor activity across KRAS G12 mutant xenograft models of pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer
60% confidenceIn preclinical models, RM-055 drove deep and durable tumor regressions across multiple tumor types and overcame resistance to prior RAS inhibition
60% confidenceTumors that had escaped prior RAS inhibitor treatment were sensitive to RM-055, which drove deep and durable regressions
60% confidenceUsing the cyclophilin A tri-complex platform, Revolution Medicines has discovered a new class of mutant-targeted RAS(ON) catalytic inhibitors designed to stimulate GTPase activity of mutant RAS variants, a long-sought goal of the RAS research community
60% confidence